On April 24, 2025 Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, reported that the Phase Ib/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma will be presented in an oral presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting in Chicago, USA, May 30-June 3, 2025 (Press release, Mabwell Biotech, APR 24, 2025, View Source [SID1234652114]). Clinical data from 3 ADC clinical studies will also be published as poster presentations at the meeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral Presentation
1. Title: 9MW2821, a novel Nectin-4 antibody-drug conjugate (ADC), combined with toripalimab in treatment-naive patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Results from a phase 1b/2 study.
Abstract Number for Publication: 4519
Presenter: Prof. Sheng Xinan, Chief Physician, Dept. of Urologic Oncology (Beijing Cancer Hospital)
Session Type and Title: Rapid Oral Abstract-Genitourinary Cancer-Kidney and Bladder
Session Date and Time: 5/31/2025, 1:15 PM-2:45 PM CDT
Poster Presentation
1. Title: Results from a phase 1/2 study of 7MW3711: A novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with advanced solid tumors.
Abstract Number: 3035
Session Type and Title: Poster Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Poster Board: 350
Session Date and Time: 6/2/2025 1:30 PM-4:30 PM CDT
2. Title: Results from a phase 1/2 study of 7MW3711: A novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with lung cancer.
Abstract Number: 3036
Session Type and Title: Poster Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Poster Board: 351
Session Date and Time: 6/2/2025 1:30 PM-4:30 PM CDT
3. Title: A first-in-human clinical study of 9MW2921, a novel TROP-2 antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Abstract Number: 3029
Session Type and Title: Poster Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Poster Board: 344
Session Date and Time: 6/2/2025 1:30 PM-4:30 PM CDT